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Dengue fever is a mosquitoborne disease caused by 4 related but antigenically distinct dengue vi-
ruses (DENVs), serotypes 1–4. Annually, ≈50–100 mil-
lion cases of dengue are reported worldwide, with 
20,000 deaths (1). Aedes mosquitoes and dengue cases 
were documented in Africa as early as 1823, and cases 
have since been reported in 34 countries in Africa (2). In 
Burkina Faso, since the first outbreak in 1925, there have 
been multiple others (2), including in 2013, 2016, and 
2017 (3–5). The 2016 outbreak included 1,061 dengue 
rapid-diagnostic test (RDT) positive cases and 15 deaths 
in the capital, Ouagadougou, with a reported case-fatal-
ity rate (CFR) of 1.2% (4,6). The 2017 outbreak included 
5,773 RDT-positive cases and 18 deaths throughout the 
country, for a CFR of 0.2% (5). These repeated outbreaks 
suggest a considerable dengue burden in the country. 
Despite this burden, data on dengue seropreva-
lence and force of infection (FOI), the rate at which 
initial or heterotypic infections are acquired, are 
scarce in Burkina Faso and Africa (7). In terms of sero-
prevalence in Burkina Faso, 1 study found the dengue 
IgG seroprevalence among 683 pregnant women and 
blood donors to be 26.3% in rural and 36.5% in urban 
settings in 2003–2004 (8). To define DENV transmis-
sion in Burkina Faso, we conducted 4 serologic sur-
veys in the same study participants in Ouagadougou 
during 2015–2017. The study targeted 3 objectives. 
First, we measured seroprevalence of DENV by IgG 
positivity at enrollment, serosurvey 1 (S1). Second, 
we estimated age-specific annual FOI, measured by 
seroconversion in the repeated follow-up surveys 
(S2–S4). Last, because a dengue outbreak occurred in 
2016, between the third and fourth serosurveys, we 
identified and compared demographic and clinical 
characteristics associated with DENV seroconversion 
in the outbreak and nonoutbreak periods. 
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Because of limited data on dengue virus in Burkina 
Faso, we conducted 4 consecutive age-stratified lon-
gitudinal serologic surveys, ≈6 months apart, among 
persons 1–55 years of age, during June 2015–March 
2017, which included a 2016 outbreak. The serocon-
version rate before the serosurvey enrollment was 
estimated by binomial regression, taking age as the 
duration of exposure, and assuming constant force of 
infection (FOI) over age and calendar time. We calcu-
lated FOI between consecutive surveys and rate ra-
tios for potentially associated characteristics based on 
seroconversion using the duration of intervals. Among 
2,897 persons at enrollment, 66.3% were IgG-positive, 
and estimated annual FOI was 5.95%. Of 1,269 enroll-
ees participating in all 4 serosurveys, 438 were IgG-
negative at enrollment. The annualized FOI ranged 
from 10% to 20% (during the 2016 outbreak). Overall, 
we observed high FOI for dengue. These results could 
support decision-making about control and preventive 
measures for dengue. 
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Methods
Study Area and Population
We selected the study area based on data, including 
seroprevalence and modeling results, available in the 
literature and existing research infrastructure (9–11). 
Ouagadougou is the capital of Burkina Faso in West 
Africa; most of the population resides in urban set-
tings (12,13). The rainy season is May–October. The 
serosurveys were conducted in a defined catchment 
population of 100,000 residents. The resident popula-
tion in Ouagadougou is stable, with an annual rate of 
migration of only 4.1% and >80% of residents owning 
their homes (14). 
Study Design
We conducted 4 serosurveys, each ≈6 months apart. 
The age-stratified sample of ≈3,000 residents 1–55 
years of age, 80% <35 years of age, reflected the age 
distribution of the general population of Ouagadou-
gou (9). In 6 preselected sectors, we randomly select-
ed households on the basis of existing census data; 
all eligible household members were offered enroll-
ment. To reach the needed sample size, if members 
of the initially invited household declined, we invited 
a neighboring household to enroll. We conducted a 
short interview and collected blood samples (9). Test 
results were shared with the participants and we fol-
lowed the same procedures with the same partici-
pants for the 3 subsequent serosurveys. 
Laboratory Testing Algorithm 
We tested samples using a Panbio Dengue IgG Indi-
rect ELISA test (Abbott Diagnostics, https://www.
abbott.com), as described elsewhere (9). Following 
the manufacturer’s guidelines, we set the IgG thresh-
old for positivity at an index value of 1.1, to detect 
levels resulting from past or recent infections of any 
serotype. An index value of 0.9–1.1 was classified 
equivocal (requiring repeated testing), and <0.9 was 
considered negative. We considered seroconversion 
of dengue IgG between the pretransmission and post-
transmission surveys to result from dengue infection. 
Statistical Analysis 
Characteristics by Dengue IgG Status at Enrollment
We present a descriptive summary by dengue IgG 
status at enrollment (seropositive vs. seronegative). 
We used χ2 or Fisher exact tests to make categorical 
pair-wise comparisons across dengue status. Contin-
uous variables were compared using Student t-test or 
analysis of variance. 
FOI Calculations
DENV infection can occur with any of the 4 serotypes 
and, assuming lifelong acquired homotypic immu-
nity, we estimated the FOI based on IgG seropositiv-
ity status (15,16). However, because IgG ELISA tests 
cannot distinguish among the 4 serotypes, infection 
in this analysis refers to seroconversion to any DENV 
serotype (15). We used binomial regression with a 
complementary log-log link function (17–20). In part 
A of the FOI analysis, in which data from the enroll-
ment serosurvey were analyzed, we estimated the av-
erage FOI over each participant’s lifetime using age 
as the time at risk. In part B of the FOI analysis, using 
data from the subset of participants who contributed 
to all 4 serosurveys, we estimated the FOI between 
consecutive surveys. We considered participants who 
were initially seronegative to be at risk for serocon-
version and used the interval between consecutive 
surveys as the time at risk. We provide details of FOI 
calculations in the Appendix (https://wwwnc.cdc.
gov/EID/article/27/1/19-1650-App1.pdf). 
Seroconversion Rate Ratios 
For the between-survey analyses, we estimated sero-
conversion rate ratios (RRs) using binomial regres-
sion models with the log time of the actual duration 
of each participant’s interval (i.e., time between con-
secutive surveys for that person) for potential risk 
factors, including age, sex, neighborhood, level of 
education, occupation, any known previous dengue 
infection, yellow fever (YF) vaccination history, and 
any self-reported signs and symptoms during the 
particular interval. As a sensitivity analysis, serocon-
version RRs were estimated for consecutive paired 
results, irrespective of results from other surveys. For 
example, if a participant was IgG-negative at S2, then 
IgG-positive at S3, we considered this seroconversion 
between S2 and S3, even if the person had been IgG-
positive at S1. 
S1–S2 covered the nonoutbreak rainy season in 
2015, S2–S3 covered the nonoutbreak nonrainy sea-
son in 2016, and S3–S4 covered the 2016 outbreak. 
To assess how demographic and clinical character-
istics are associated with DENV seroconversion and 
the difference in patterns in the outbreak (S3–S4) 
compared with those in nonoutbreak periods (S1–
S2 and S2–S3), we compiled a descriptive summary 
of demographic and clinical characteristics for par-
ticipants at risk (IgG-negative) at each serosurvey, 
broken down between participants who had or had 
not seroconverted by the subsequent serosurvey. 
All analyses were performed using SAS version 9.4 
(https://www.sas.com). 
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Ethics Considerations
The study protocol received ethics approvals from the 
institutional review boards of the International Vaccine 
Institute, the London School of Hygiene and Tropical 
Medicine, the National Ethical Committee for Health 
Research of Burkina Faso, and the Ethics Committee of 
the Centre Hospitalier de l’Université de Montréal at 
University of Montreal. We obtained written consent 
forms from each participant >18 years old. For par-
ticipants 8–17 years old, we obtained an assent form 
from the participant and an informed consent from >1 
parent or legal guardian. For participants ≤7 years old, 
we obtained an informed consent from >1 parent or 
legal guardian. 
Results
We obtained complete demographic (age and neigh-
borhood) and laboratory data for 2,897 of 3,026 par-
ticipants (Figure 1). At enrollment (S1), in June 2015, 
1,920 (66.3%) of 2,897 participants were IgG positive. 
At S2, in December 2015, 1,417 (67.2%) of 2,109 par-
ticipants were IgG positive. At S3, in May 2016, 1,400 
(66.5%) of 2,106 participants were IgG positive. At 
S4, in March 2017, 1,121 (67.9%) of 1,651 participants 
were IgG positive. 
Characteristics by Dengue IgG Status at Enrollment
Based on data from the 2,897 participants with com-
plete information, 82% of 1–4-year-olds and 65% of 
5–9-year-olds were IgG negative and therefore at 
risk of infection at the start of the study (Table 1). 
IgG positivity increased with age, so that by age 26, 
IgG positivity reached 80% (Figure 2). The binomial 
regression based on IgG positivity by age at enroll-
ment, assuming the FOI was constant over ages and 
calendar time (part A), resulted in an annual FOI of 
5.95% (95% CI 5.66–6.24) (Figure 2). 
Annual FOI in IgG-Negative Participants Who  
Contributed to All 4 Serosurveys
In part B, we calculated annualized FOI among par-
ticipants who had been IgG negative at the preceding 
serosurvey using binomial regression with the inter-
survey interval, calculated in years, as the time at risk. 
For the interval S1–S2, FOI per year was 14.0% (95% 
CI 9.5%–18.4%); for the interval S2–S3, 9.6% (95% CI 
5.4%–13.8%); and for the interval S3–S4, 20.3% (95% 
CI 16.1%–24.5%) (Figure 1). The mean duration was 
0.53 years (≈6 months) for interval S1–S2; 0.44 years 
for S2–S3; and 0.84 years for S3–S4. Age-specific an-
nual FOIs were calculated and older age groups with 
<5 seronegative participants were merged. For inter-
vals S1–S2 and S2–S3, FOI was higher for older par-
ticipants (Figure 1). For interval S3–S4, high FOIs of 
30% per year were found in participants 15–19 and 
25–29 years of age. 
Seroconversion RRs from Outbreak Versus  
Nonoutbreak Intervals 
We analyzed data from each pair of surveys, not 
restricted to data from participants in all 4 surveys, 
to examine differences in dengue seroconversion 
Figure 1. Flowchart of participant enrollment and graphs of annual force of infection rates during a rainy season (A), a nonrainy season 
(B), and the 2016 dengue outbreak (C)  in study of force of infection for dengue virus, Ouagadougou, Burkina Faso, June–July 2015. 
Labels along x-axes (e.g., 0–4) indicate age ranges in years. Error bars indicate 95% CIs. To be considered complete, records had to 
contain lab results and basic demographic information. Seroconversion rates in the paired analyses were based solely on results from 
one survey to the next (e.g., S2–S3). Dengue serostatus in previous or subsequent surveys was not considered. S, serosurvey. 
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during outbreak versus nonoutbreak intervals. During 
nonoutbreak interval S1–S2 (analysis sample = 1,494), 
33 (7.3%) of 455 participants at risk (i.e., IgG negative at 
S1), showed seroconversion. During nonoutbreak in-
terval S2–S3 (analysis sample = 1,488), 23 (5.2%) of 443 
participants at risk (i.e., IgG negative at S2), showed 
 
Table 1. Demographic and clinical characteristics of participants in study of force of infection for dengue virus, by dengue IgG status at 
enrollment, Ouagadougou, Burkina Faso, June–July 2015* 
Characteristics All participants,† N = 2,897 Seropositive,‡ n = 1,920 Seronegative,‡ n = 977 p value§ 
Mean age, SD 22.32 (13.92) 27.02 (13.36) 13.08 (9.74) <0.001 
Age group, y    <0.001 
 1–4  208 (7.2) 37 (1.9) 171 (17.5)  
 5–9  410 (14.2) 142 (7.4) 268 (27.4)  
 10–14  384 (13.3) 189 (9.8) 195 (20.0)  
 15–19  379 (13.1) 243 (12.7) 136 (13.9)  
 20–29  694 (24.0) 560 (29.2) 134 (13.7)  
 30–39  410 (14.2) 357 (18.6) 53 (5.4)  
 40–49  264 (9.1) 249 (13.0) 15 (1.5)  
 50–55  148 (5.1) 143 (7.5) 5 (0.5)  
Sex¶    <0.001 
 M 1,154 (39.9) 700 (36.5) 454 (46.5)  
 F 1,741 (60.1) 1,218 (63.5) 523 (53.5)  
Ethnicity    0.712 
 Burkinabé 2,871 (99.6) 1,906 (99.6) 965 (99.5)  
 Others 13 (0.5) 8 (0.4) 5 (0.5)  
Neighborhood/sector    <0.001 
 Sector 22 447 (18.2) 342 (20.5) 105 (13.3)  
 Sector 25 510 (20.7) 395 (23.6) 115 (14.6)  
 Juvenat fille 517 (21.0) 353 (21.1) 164 (20.8)  
 Pazani 433 (17.6) 281 (16.8) 152 (19.2)  
 Zongo 547 (22.2) 297 (17.8) 250 (31.7)  
 Nioko 8 (0.3) 4 (0.2) 4 (0.5)  
Occupation    <0.001 
 Student 1,033 (35.8) 586 (30.6) 447 (46.0)  
 Housewife 885 (30.7) 666 (34.8) 219 (22.5)  
 Small business owner 163 (5.7) 130 (6.8) 33 (3.4)  
 Unskilled worker 153 (5.3) 124 (6.5) 29 (3.0)  
 Government official 92 (3.2) 77 (4.0) 15 (1.5)  
 Private sector employee 82 (2.8) 66 (3.5) 16 (1.7)  
 Merchant 55 (1.9) 46 (2.4) 9 (0.9)  
 Retired 53 (1.8) 26 (1.4) 27 (2.8)  
 Farmer 49 (1.7) 35 (1.8) 14 (1.4)  
 Skilled worker 43 (1.5) 32 (1.7) 11 (1.1)  
 Service sector worker 43 (1.5) 34 (1.8) 9 (0.9)  
Education level    <0.001 
 Illiterate 887 (30.7) 596 (31.1) 291 (29.9)  
 Literate, no education 72 (2.5) 58 (3.0) 14 (1.4)  
 1–6 y of school 803 (27,8) 455 (23.8) 348 (35.8)  
 7–10 y of school 551 (19.1) 388 (20.3) 163 (16.8)  
 11–13 y of school 274 (9.5) 200 (10.4) 74 (7.6)  
 >University 210 (7.5) 171 (8.9) 39 (3.0)  
 Others# 57 (2.0) 39 (2.0) 18 (1.9)  
Self-reported preexisting conditions     
 Cardiovascular 113 (4.0) 100 (5.3) 13 (1.4) <0.001 
 Diabetes 10 (0.4) 7 (0.4) 3 (0.3) 0.817 
 Lung disease 19 (0.7) 17 (0.9) 2 (0.2) 0.034 
 Cerebrovascular 27 (0.9) 18 (0.9) 9 (0.9) 0.990 
 Musculoskeletal 101 (3.5) 82 (4.3) 19 (2.0) 0.002 
 Gastrointestinal 193 (6.7) 148 (7.8) 45 (4.7) 0.002 
 Anemia 10 (0.4) 2 (0.1) 8 (0.80) 0.002 
 Others 108 (3.8) 79 (4.1) 29 (3.0) 0.139 
Self-reported previous dengue    <0.001 
 Yes 13 (0.5) 13 (0.7) 0 
 
 No 2,421 (84.7) 1,635 (86.0) 786 (82.1)  
 Unknown 426 (14.9) 254 (13.4) 172 (18.0)  
*Values are no. (%) except as indicated.  
†Total participants enrolled at serosurvey 1. 
‡Results of IgG indirect ELISA among participants at serosurvey 1. 
§p values based on χ2 test.  
¶2 individuals with missing information on sex. 
#Religious and other informal education. 
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seroconversion. During outbreak interval S3–S4 (anal-
ysis sample = 1,401) 78 (17.1%) of 455 participants at 
risk (i.e., IgG negative at S3), showed seroconversion. 
We compiled demographic and clinical characteristics 
of participants with IgG seroconversion compared 
with participants who remained IgG negative during 
each interval (Table 2, https://wwwnc.cdc.gov/EID/
article/27/1/19-1650-T2.htm). 
To assess how these variables might be associated 
with changes in rates of seroconversion, we estimated 
RRs of seroconversion during the intervals. We found 
that older age was positively associated with an in-
creased rate of seroconversion. Compared with those 
1–4 years of age, participants 25–55 years of age had 
higher seroconversion over S1–S2 [RR 4.1 (95% CI 
1.4–15.0)]; both 15–24-year-old participants [RR 4.6 
(95% CI 1.4–17.4)] and 25–55-year-old participants 
[RR 9.1 (95% CI 12.9–34.2)] had higher seroconversion 
over S2–S3 (Table 3). 
Discussion
Our study provides data on population-based sero-
prevalence and rates of DENV seroconversion that 
may help with assessing the largely undocumented 
burden of dengue fever in Africa. The dengue burden 
in Africa has been conjectured to be similar to that 
in the Americas but has been largely unrecognized 
and masked by other illnesses with similar symptoms 
(21,22). In particular, the major strength of this study 
was that we longitudinally followed the same partici-
pants using 4 repeated serosurveys to measure the 
FOI of dengue in Burkina Faso. 
Although IgG ELISA test results might be influ-
enced by cross-reactivity with different flaviviruses, 
our estimate of seroprevalence was comparable to 
prevalence estimates from other studies, all tested us-
ing IgG ELISA: 61% of participants 1–65 years of age 
in Colombia (25); 83.1% in participants 15–19 years 
of age in Tahiti (26); 74% in participants in a low so-
cioeconomic area in Recife, Brazil (27); and 68.7% in 
participants in Salvador, Brazil (28). The overall pro-
portion of IgG-positive participants remained simi-
lar across the surveys, although it was highest at S4 
(68%). The small increase in seropositivity despite an 
outbreak between S3 and S4 may have resulted from 
different participants being lost to follow-up at each 
consecutive survey. Such losses were substantial dur-
ing the S1–S2 and S3–S4 intervals. The mean age of 
participants lost during S1–S2 was 20.7 years (95% CI 
19.3–22.0) and was 23.7 (95% CI: 22.5–24.9) during S3–
S4. The mean age of the participants was 22.2 years 
(95% CI 21.6–22.9) during S1–S2 and 21.6 (95% CI 
21.0–22.2) during S3–S4. For S1–S2, the mean age was 
not significantly different between nonparticipants 
Figure 2. Seroprevalence, measured by IgG ELISA, of dengue IgG by age at enrollment and fitted prevalence using the FOI per year 
in study of force of infection for dengue virus, Ouagadougou, Burkina Faso, June–July 2015. Graph shows observed seroprevalence at 
enrollment among all 2,897 participants and fitted seroprevalence using FOI. In the FOI analysis part A, the FOI per year was 0.0595 
(95% CI 0.0566–0.0624), estimated by binomial regression, with the assumption of constant risk across ages and calendar time prior to 
the enrollment serosurvey, and a complementary log-log link, with log(midpoint of age) as an offset. The intercept is interpreted as the 
logarithm of the FOI. FOI, force of infection.
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and remaining participants, but lost participants 
were significantly older for S3–S4; participants lost 
at follow-up might have tended to be IgG positive, 
plausibly resulting in underestimating IgG positivity 
at the follow-up survey. While decreasing representa-
tiveness is a limitation, we based FOI calculations on 
seroconversion meaning they likely would not have 
been substantially affected. We found apparent sero-
reversion from seropositive to seronegative in <3% of 
the paired samples: 29 during S1–S2, 14 during S2–S3; 
and 38 during S3–S4. However, we could not distin-
guish whether such cases were due to test errors or 
waning immunity. 
Data from the baseline serosurvey in this study 
(part A) resulted in an annual FOI of 6.0%, although 
this assumes that it was constant over age and calen-
dar time. This finding is comparable with estimates 
from other regions, such as Sri Lanka at 14% per year 
(15); Colombia at 8.7% (22); and a low socioeconomic 
area in Recife, Brazil, at 5.3% (25). Our model seems 
to capture the increase in baseline seroprevalence 
with age (Figure 1). However, any given age profile 
in a cross-sectional study can result from different 
combinations of incidence varying over age or over 
calendar time (27). Therefore, the estimated FOI 
from the baseline survey is subject to more limita-
tions than FOIs estimated from the paired surveys. 
Nonetheless, our data support that dengue may be 
a bigger public health problem in Africa than is cur-
rently recognized. 
From the repeat surveys (part B) for which we 
knew the exact duration of the intervals, we could 
measure the FOI more directly without assuming a 
constant value over age, providing a more accurate 
estimate of the magnitude of transmission. These es-
timates were higher than the 6% annual FOI based 
on the enrollment survey. Among 1,269 participants 
with IgG results from all 4 serosurveys, annual FOIs 
were 14% for S1–S2, 10% for S2–S3, and 20% for S3–S4. 
Testing of paired samples showed that 7.3% (33/455) 
seroconverted during S1–S2, 5.2% (23/443) during 
S2–S3, and 17.1% (78/455) during S3–S4. As we ex-
pected, the annualized estimates of rates were ≈2 
times the simple proportions for the first 2 intervals. 
For the third interval (S3–S4), the annualized FOI was 
≈1.5 times (12/8 months) the proportion seroconvert-
ing, because the conversion between proportions and 
rates is less linear for higher values. 
The paired survey analyses did not require an 
assumption of constant FOI before the study and 
showed that FOI varied markedly across time within 
the study. In particular, a high annualized FOI (20%) 
was observed between S3–S4, coinciding with a ma-
jor outbreak. However, even during nonoutbreak in-
tervals, we found considerable dengue transmission; 
annualized FOIs ranged from 10% (in a nonrainy 
 
Table 3. Univariable binomial regression showing ratio of rates of seroconversion in study of force of infection for dengue virus, based 
on results of IgG indirect ELISA assays, Ouagadougou, Burkina Faso, June–July 2015* 
Characteristics 
S1–S2,† N = 455, IgG-S (n = 33) 
vs. IgG-N (n = 422) 
 
S2–S3,† N = 443, IgG-S (n = 23) 
vs. IgG-N (n = 420) 
 
S3–S4,† N = 455, IgG-S (n = 78) 
vs. IgG-N (n = 377) 
IgG-S rate (95% CI) p value‡ IgG-S rate (95% CI) p value‡ IgG-S rate (95% CI) p value‡ 
Age range, y  0.006   0.002   0.038 
 1–4 Referent   Referent§ 
 
  Referent  
 5–9 0.70 (0.19–2.84) 0.65 (0.31–1.37) 
 10–14 1.00 (0.27–4.05) 2.25 (0.53–9.52) 1.00 (0.48–2.12) 
 15–24 1.99 (0.65–7.35) 4.55 (1.37–17.38) 1.77 (0.91–3.60) 
 25–55 4.11 (1.37–14.99) 9.13 (2.87–34.20) 1.29 (0.55–2.94) 
Sex  0.155   0.166   0.686 
 M Referent   Referent   Referent  
 F 1.67 (0.84–3.51) 
 
 1.83 (0.80–4.55) 
 
 1.10 (0.70–1.72) 
 
Preexisting conditions¶  0.016   0.017   0.433 
 None/unknown Referent   Referent   Referent  
 Yes 2.67 (1.13–5.67) 
 
 3.11 (1.12–7.48) 
 
 1.29 (0.64–2.34) 
 
Occupation  0.935   0.025   0.177 
 Student Referent   Referent   Referent  
 At home# 1.11 (0.45–2.56) 3.81 (1.45–11.05) 1.64 (0.96–2.75) 
 Others** 1.15 (0.50–2.54) 1.70 (0.53–5.45) 1.16 (0.66–2.01) 
Level of education  0.917   0.191   0.164 
 Illiterate/no schooling Referent   Referent   Referent  
 Elementary 1.19 (0.52–2.89) 0.39 (0.12–1.06) 0.80 (0.45–1.42) 
 >Secondary  1.15 (0.48–2.85) 0.61 (0.23–1.55) 1.33 (0.78–2.32) 
*Bold indicates statistical significance. IgG-S, IgG seroconverted; IgG-N, IgG negative; S, serosurvey. 
†Paired survey intervals. S1–S2: July–December 2015; S2–S3: January 2016–May 2016; S3–S4: June 2016–March 2017. 
‡p values based on χ2 test. 
§Age groups 1–4 and 5–9 merged due to data scarcity in seroconverted participants. 
¶Based on self-report by participants. 
#Housewife, retired, unemployed. 
**Business owners, employees, workers, etc. 
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season, such as S2–S3) to 14% (in a rainy season, 
S1–S2) (28). Little comparable information from the 
region is available, but these rates are comparable to 
the 8.7% per year reported from Colombia (23). 
These annual rates of infection, measured by 
seroconversion, may include both initial and subse-
quent heterotypic infection, because these are indis-
tinguishable by IgG ELISA. However, in our analysis, 
the influence of past infection is minimal, because we 
focused on participants with IgG-negative status at 
enrollment for calculations of FOIs between surveys. 
This study was unable to distinguish participants 
with single or multiple infections during the study 
period. Furthermore, among those with multiple in-
fections, cyclical dominance among DENV serotypes 
is observed in regions with better-documented den-
gue endemicity (29,30). However, cocirculation of 
multiple DENV serotypes in Burkina Faso has yet 
to be fully demonstrated. Thus, in our study, we cal-
culated an overall FOI, for the totality of serotypes 
(20,31). Still, we recognize the need for more in-depth 
analyses using neutralization assays to understand 
serotype-specific transmission patterns in Africa. 
In part B of the study, without having to assume 
that risk is constant over age, we found that FOI was 
higher in older than in younger participants, although 
these findings are based on small numbers, given that 
most people had already seroconverted at younger 
ages. FOI increased with age in the intervals of the 
nonoutbreak times (S1–S2 and S2–S3), which has also 
been found in Colombia (23). Our data are from IgG 
seroconversion rather than clinical dengue, but inci-
dence of dengue fever in the 2016 outbreak in Burki-
na Faso was also higher among teenagers and young 
adults (4,6,32). In contrast, in the outbreak interval 
S3–S4, the FOI was similar across ages (13%–34%), 
possibly suggesting the emergence of a different sero-
type with little preexisting population immunity (20). 
Without much data on serotype-specific DENV inci-
dence in Burkina Faso, previous studies and reports 
of ministry of health and World Health Organization 
investigations suggest that the 2016 outbreak was 
mainly caused by DENV-2 (4,6,32).
Myalgia during S1–S2, arthralgia during S2–S3, 
and fatigue during S3–S4 were positively associated 
with seroconversion with statistical significance. 
Whereas cases of seroconversion may have been as-
sociated with either mild or subclinical illnesses, par-
ticipants were asked whether they had experienced 
these symptoms in the interval since the previous sur-
vey. These symptoms are common in dengue illness; 
myalgia and arthralgia were listed in the 1997 World 
Health Organization dengue case classifications, and 
fatigue or lethargy in 2009 classifications (33–35). 
However, because these self-reported symptoms 
were recorded at intervals of 6–8 months, without 
prompt investigation to identify a cause, we cannot 
conclude that any associations with seroconversion 
are causal. 
This study is subject to several limitations. First, 
the generalizability of this study is limited by par-
ticipants all being recruited from the urban popula-
tion in the capital city. The magnitude and patterns 
of DENV transmission may differ in other regions of 
Burkina Faso, including rural areas, with different 
age profiles, ecologic settings, or socioeconomic con-
ditions. Also, although a large number of participants 
(1,269) participated in all 4 serosurveys, a substan-
tial number of original participants missed surveys. 
Those participants who missed >1 surveys were more 
likely to be older than those who participated in all 
surveys. This shortfall could have led us to underes-
timate prevalence. 
Second, our results were based on serologic test-
ing using IgG ELISA. Further analyses using neu-
tralization assays are planned, but no confirmatory 
testing was applied to verify the IgG results. For es-
timating dengue FOI, serologic cross-reaction with 
other flaviviruses affecting the observed dengue IgG 
rates is a commonly reported limitation (36,37). Ul-
timately, this limitation could result in inaccurate 
seroprevalence and FOI estimates because antibod-
ies against nondengue flaviviruses could have been 
detected (15,38). In particular, Zika virus has been re-
ported in Burkina Faso (39,40), as have outbreaks of 
YF in 1998, 2003, and 2004 (41–43). Vaccine-induced 
YF antibodies could also result in interference with 
the specificity of IgG ELISA (38). In our data, at each 
of the serosurveys, <5% of participants answered that 
they had received YF vaccination; although subject to 
recall bias, this rate is much lower than the coverage 
rate of 85% reported by the Expanded Program on Im-
munization in 2007 (42). Using self-reported YF vac-
cination history as a proxy for YF virus seropositiv-
ity, we found no difference in IgG positivity between 
participants reporting and not reporting vaccination, 
a finding supported by others (38,44). 
Despite the possible effect of cross-reactivity on 
dengue ELISAs, 2 studies reported a concordance 
level of 99% between the plaque reduction neutral-
ization test (PRNT) and dengue IgG results (37,45). 
Also, when IgG ELISA results were verified by us-
ing serologic data among 13,661 participants from 13 
countries to estimate dengue FOI, IgG ELISA results 
were confirmed by 50% PRNT in >97% of the IgG-
positive samples (20). Samples from 277 healthy 
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adults in a rural district in Malaysia were tested with 
the same ELISA test used in our study, and PRNT 
was performed on a subset of IgG-positive samples 
(46). Evidence of past infection was found in 75.5% 
(209/277) of participants and, of 96 samples ran-
domly selected to undergo PRNT testing, all 96 were 
dengue-confirmed with >50% plaque reduction for 
DENV and showed that the detected antibodies were 
specific to dengue virus (46). 
The sensitivity of this commercial DENV IgG in-
direct ELISA was reported as 99.2% and the specific-
ity as 96.2% when compared with the hemagglutina-
tion inhibition (HI) method (47). A study compared 
performance of IgG ELISA to that of HI testing in 
a serosurvey of 327 children in Tahiti and reported 
sensitivity and specificity, as well as agreement be-
tween the 2 tests, to be >83% for all DENV serotypes 
(24). Another study reported 90.9% sensitivity and 
92.9% specificity of the IgG indirect ELISA when 
compared with HI, also with a high correlation be-
tween the tests (48). Whereas those data are from 
outside of Africa, where a different and unknown 
composition of flaviviruses may be circulating, the 
results indicate a high degree of agreement between 
IgG ELISA and more confirmatory and better vali-
dated tests, such as HI and PRNT. 
If cross-reactivity across other flaviviruses were 
to result in misclassifications, leading to a high rate of 
false positives, our findings would be overestimates 
of the true disease prevalence and FOI. However, 
given the high concordance between IgG and PRNT 
or HI assay results based on available data and be-
cause we analyzed data from paired serosurveys of 
participants who were IgG negative at enrollment, we 
believe that our results were minimally affected by 
this issue. 
In conclusion, our estimates of both seroprev-
alence and FOI were comparable with those from 
dengue-endemic countries in the Americas. Re-
peated outbreaks indicate a considerable level of 
DENV transmission in Ouagadougou, but the ex-
tent of transmission and hyperendemicity needs to 
be further verified. Specifically, additional longitu-
dinal evaluation with confirmatory tests and linked 
clinical evaluation of dengue fever in the general 
population in the region would be necessary to 
further validate our findings. Seroprevalence and 
FOI are important factors to be considered when 
making evidence-based decisions to implement in-
terventions for prevention and control, including 
vaccine introduction. In the absence of other reli-
able data, our findings on dengue seroprevalence 
and FOI based on consecutive serosurveys provide 
practical evidence that could be used to support 
policy decisions. 
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